 |
|
|
| |
ALS-2200, A Novel Once-daily Nucleotide HCV Polymerase Inhibitor, Demonstrated Potent Antiviral Activity In Treatment-naïve Patients with Compensated Cirrhosis or Genotype 2-4 Chronic Hepatitis C
|
| |
| |
Reported by jules Levin
APASL 2013 June 6-10 Singapore
P. Marcellin1, S.Popa2, A. Streinu-Cercel3, N. Boyer1, D. Dospinoiu3, A, Patat4, N. Ghicavii2, V.Garg5, R.S.Kauffman5, M.Koziel5, M.J. Tong6, S.M.Chanda7, Q.Zhang7, C.Westland7, L.Beigelman7, L.M.Blatt7, and J.Fry7
Hopital Beaujon, Clichy, France, 2. Republican Clinical Hospital, Chisinau, Moldova, 3. National Institute of Infectious Diseases, Bucharest, Romania, 4. Biotrial, Rennes, France, 5. Vertex Pharmaceuticals Incorporated, Cambridge, MA, USA, 6. Liver Center, Huntington Medical Research Institutes, Pasadena, CA, USA, 7. Alios BioPharma, South San Francisco, CA, USA
|
| |
|
|
|
|
|
